MATRIX METALLOPROTEINASES AND THEIR TISSUE INHIBITORSIN OVARIAN CANCER CLINICAL COURSE AND PROGNOSIS

 Download full text (PDF)

E.S. Gershtein (1), D.N. Kushlinsky (2), L.V. Adamyan (2), I.V. Tereshkina (1), K.P. Laktionov (1)
1 -N.N. Blokhin Russian Cancer Research Center, Moscow
2 -Academician V.I. Kulakov Research Center of Obstetrics, Gynecology, and Perinatology, Moscow

Publications devoted to the role of various representatives of matrix metalloproteinases (MMPs) family and their tissue inhibitors in ovarian cancer in differential diagnostics, prognosis and in the development of new treatment modalities are critically analyzed in this review. It is concluded that gelatinases/collagen IV collagenases – MMP-9 and MMP-2, matrilysin (MMP-7), type 1 tissue MMP inhibitor (TIMP-1) and membrane-type MMP-1 can be considered as the most perspective markers for differential diagnostics and ovarian cancer prognosis. Existing methods of suppression of MMPs activity including application of specific inhibitors permit to reduce ovarian cancer cells invasiveness in vitro, but need further refinement for introduction into clinical practice.
Keywords: 
matrix metalloproteinases, tissue matrix metalloproteinase inhibitors, ovarian cancer, diagnostics, prognosis, molecular targeted therapy